AX-2025-020919 · Pemvidutide · CPC lot CPC-2507-H2201

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 32 min gradient, 214 nm	97.85	% area	≥ 96.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	2.15	% area	≤ 4.0	PASS
Largest single impurity	RP-HPLC — truncated (3-39)	0.99	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4679.4014	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	4679.4150	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.9	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	86.93	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	85.06	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	2.17	mg	1.8 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	1.846	mg	1.8 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	102.6	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.31	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	8.26	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.50	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	1.22	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White powder, no defined cake (melt-back)	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.54	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 32 min gradient	20.83	min	21.61 ± 0.50 (normalised)	FAIL
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.15	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	75,387	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib2]-diastereomer	0.69	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 32 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 75,387, and skew follows the reported asymmetry factor of 1.15. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.99 % impurity against a 97.85 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Pemvidutide — main peak	20.83	4,755,813	97.85	—
2	truncated (3-39)	19.18	48,117	0.99	-222.112
3	[D-Aib2]-diastereomer	20.62	36,452	0.75	0.000
4	aspartimide (−18 Da)	21.45	11,179	0.23	-18.011
5	des-EDA linker (−60 Da)	19.89	8,749	0.18	-60.048
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4679.4014 Da, computed from C218H336N48O66. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4679.4150 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	780.9075	780.9098	0.0023	8.6
5+	936.8876	936.8903	0.0027	56.8
4+	1170.8576	1170.8610	0.0034	100.0
3+	1560.8077	1560.8123	0.0046	55.2

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.31
Counter-ion (TFA)	ion chromatography	8.26
Residual solvent + inorganic residue	estimated	0.50
Total peptide content	by difference	86.93
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.0	97.85	divergence -0.35 pp vs batch median
Total impurities (% area)	1.39	2.15
Largest single impurity (% area)	0.64	0.99
Water (%)	3.6	4.31
Counter-ion (%)	not stated	8.26
Peptide content (%w/w)	not stated	86.93
Endotoxin (EU/mg)	0.70	1.22
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (19 d) → laboratory (courier, cold pack, 11 d) → assay.
Assay date: 04 Nov 2025
Submitted to the index: 14 Nov 2025
Laboratory: VendorInvestigate, Riga, Latvia
Method basis: 32 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot CPC-2507-H2201 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020913	CPC-2507-H2201	Janoshik	2025-Q4	97.93	4.02	90.7	Buyer-sourced	3	MARGINAL
AX-2025-020914	CPC-2507-H2201	Kestrel	2025-Q4	98.41	4.35	96.8	Buyer-sourced	3	MARGINAL
AX-2025-020915	CPC-2507-H2201	Nordanalyt	2025-Q4	98.51	3.52	—	Supplier-supplied	3	MARGINAL
AX-2025-020916	CPC-2507-H2201	Medutest	2025-Q4	98.66	3.85	—	Supplier-supplied	3	MARGINAL
AX-2025-020917	CPC-2507-H2201	PeptideMeter	2025-Q4	98.29	3.78	—	Supplier-supplied	3	MARGINAL
AX-2025-020918	CPC-2507-H2201	Janoshik	2025-Q4	98.17	3.53	103.8	Supplier-supplied	3	MARGINAL
AX-2025-020920	CPC-2507-H2201	PeptideMeter	2025-Q4	98.81	4.43	97.0	Supplier-supplied	3	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Pemvidutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020916	CPC	CPC-2507-H2201	Medutest	2025-Q4	98.66	3.85	—	Supplier-supplied	3	MARGINAL
AX-2025-020914	CPC	CPC-2507-H2201	Kestrel	2025-Q4	98.41	4.35	96.8	Buyer-sourced	3	MARGINAL
AX-2025-020920	CPC	CPC-2507-H2201	PeptideMeter	2025-Q4	98.81	4.43	97.0	Supplier-supplied	3	MARGINAL
AX-2025-020918	CPC	CPC-2507-H2201	Janoshik	2025-Q4	98.17	3.53	103.8	Supplier-supplied	3	MARGINAL
AX-2025-020917	CPC	CPC-2507-H2201	PeptideMeter	2025-Q4	98.29	3.78	—	Supplier-supplied	3	MARGINAL
AX-2025-020913	CPC	CPC-2507-H2201	Janoshik	2025-Q4	97.93	4.02	90.7	Buyer-sourced	3	MARGINAL
AX-2025-020915	CPC	CPC-2507-H2201	Nordanalyt	2025-Q4	98.51	3.52	—	Supplier-supplied	3	MARGINAL
AX-2025-018613	QYB	QYB-2502-V5083	Nordanalyt	2025-Q3	98.10	4.15	—	Supplier-supplied	3	MARGINAL

Other recent CPC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043368	N-Acetyl Semax Amide	CPC-2602-D2941	Medutest	2026-Q3	98.79	6.05	102.1	Supplier-supplied	0	PASS
AX-2026-043335	Liraglutide	CPC-2602-G1978	Janoshik	2026-Q3	97.29	4.91	—	Laboratory-retained	1	FAIL
AX-2026-043283	L-Carnosine	CPC-2603-G1651	Medutest	2026-Q3	98.10	10.12	91.8	Supplier-supplied	1	FAIL
AX-2026-043365	BPC-157	CPC-2602-W2646	Medutest	2026-Q3	98.56	2.80	—	Supplier-supplied	1	MARGINAL
AX-2026-043332	Liraglutide	CPC-2602-G1978	Janoshik	2026-Q3	97.16	4.88	91.3	Supplier-supplied	1	FAIL
AX-2026-043289	L-Carnosine	CPC-2603-G1651	Janoshik	2026-Q3	98.01	10.52	—	Buyer-sourced	1	FAIL
AX-2026-043287	L-Carnosine	CPC-2603-G1651	Janoshik	2026-Q3	98.35	9.89	93.2	Supplier-supplied	2	FAIL
AX-2026-043367	N-Acetyl Semax Amide	CPC-2602-D2941	Nordanalyt	2026-Q3	99.39	6.16	92.4	Supplier-supplied	0	PASS